Abstract P2-08-08: A phase 1 study of RAD1901, an oral selective estrogen receptor degrader, to determine changes in the18F-FES uptake and tumor responses in ER-positive, HER2-negative, advanced breast cancer patients

2017 ◽  
Author(s):  
EGE de Vries ◽  
CM Venema ◽  
AWJM Glaudemans ◽  
A Jager ◽  
F Garner ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Phase 1 ◽  
Advanced Breast ◽  
Breast Cancer Patients ◽  
Phase 1 Study ◽  
Er Positive

A Phase 1 study of RAD1901, an oral selective estrogen receptor degrader, in ER positive, HER2 negative, advanced breast cancer patients.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. TPS627-TPS627 ◽  
Author(s):  
Elisabeth De Vries ◽  
Clasina Marieke Venema ◽  
Andor W. J. M. Glaudemans ◽  
Lorraine Fitzpatrick ◽  
Dinesh Purandare ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Phase 1 ◽  
Advanced Breast ◽  
Breast Cancer Patients ◽  
Phase 1 Study ◽  
Er Positive
Sign in / Sign up

Export Citation Format

Share Document